Scabo 12

Dosage & Administration

For Treatment (If COVIO Positive): 2 Tablets of Ivermectin 6 mg once daily for 5 days. (2+0+0 for 5 days).
For Prophylaxis: Single-dose as mentioned below to be taken on Day 1 & same dose on Day 7.

• Body Weight 15-24 kg: 1 Tablet of Ivermectin 3 mg

• Body Weight 25-35 kg: 1 Tablet of Ivermectin 6 mg

• Body Weight 36-50 kg: 1 Tablet of Ivermectin 6 mg + 1 Tablet of Ivermectin 3 mg

• Body Weight 51-65 kg: 2 Tablets of Ivermectin 6 mg

• Body Weight 66-79 kg: 2 Tablets of Ivermectin 6 mg + 1 Tablet of Ivermectin 3 mg

• Body Weight >80 kg: 3 Tablets of Ivermectin 6 mg

Strongyloidiasis: The recommended dosage of Ivermectin for the treatment of strongyloidiasis is a single oral dose designed to provide approximately 200 mcg/kg of body weight. Patients should take tablets on an empty stomach with water. In general, additional doses are not necessary. However, follow-up stool examinations should be performed to verify eradication of infection.

Dosage Guidelines for Ivermectin for Strongyloidiasis:

• Body Weight (kg) 15-24: Dose 3 mg/kg

• Body Weight (kg) 25-35: Dose 6 mg/kg

• Body Weight (kg) 36-50: Dose 9 mg/kg

• Body Weight (kg) 51-65: Dose 12 mg/kg

• Body Weight (kg) 66-79: Dose 15 mg/kg

• Body Weight (kg) >80: Dose 200 mcg/kg

Onchocerciasis: The recommended dosage of Ivermectin is a single oral dose designed to provide approximately 150 mcg of Ivermectin per kg of body weight on an empty stomach with water, the most commonly used dose interval is 12 months. For the treatment of individual patients, retreatment may be considered at intervals as short as 3 months.

Dosage Guidelines for Ivermectin for Onchocerciasis:

• Body Weight (kg) 15-25: Dose 3 mg/kg

• Body Weight (kg) 26-44: Dose 6 mg/kg

• Body Weight (kg) 45-64: Dose 9 mg/kg

• Body Weight (kg) 65-84: Dose 12 mg/kg

• Body Weight (kg) >85: Dose 150 mcg/kg

Interaction

When ivermectin was co-administered with warfarin, post-marketing complaints of elevated INR (International Normalized Ratio) were infrequent.

Contraindications

It is not recommended for those who are hypersensitive to any of the product's ingredients.

Side Effects

Strongyloidiasis: The following adverse reactions were recorded as potentially, probably, or definitely connected to Ivermectin in four clinical studies with a total of 109 patients who received one or two doses of 170 to 200 mcg/kg of Ivermectin.
The entire body: asthenia/fatigue (0.9%), abdominal pain (0.9 percent )
Anorexia (0.9 percent), constipation (0.9 percent), diarrhea (1.8 percent), nausea (1.8 percent), and vomiting (0.9 percent) (0.9 percent ) Nervous System/Psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), and tremor (0.9%) (0.9 percent )
Pruritus (2.8%), rash (0.9%), and urticaria (0.9%) are the most common skin complaints (0.9 percent ).
Antiepileptic Drug Withdrawal: Brivaracetam should be tapered off gradually.

Onchocerciasis: arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. These have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. The following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and Stevens-Johnson syndrome.

Pregnancy & Lactation

Pregnancy Classification C. Ivermectin does not appear to be fetotoxic to a growing fetus in any way. However, no suitable and well-controlled studies in pregnant women have been conducted. Because the safety of ivermectin in pregnancy has not been proved, it should not be used during pregnancy.
Mothers who are breastfeeding: Ivermectin is excreted in small amounts in human milk. Treatment of lactating mothers should be conducted only when the danger of delayed treatment to the mother surpasses the potential risk to the newborn.

Precautions & Warnings

Microfilaricidal medicines, such as diethylcarbamazine citrate (DEC-C), have been documented in the past to elicit cutaneous and/or systemic reactions of different severity (the Mazzotti reaction) as well as ophthalmological reactions in onchocerciasis patients. These reactions are most likely allergic and inflammatory responses to microfilariae death. Patients treated with Ivermectin for onchocerciasis may experience these reactions in addition to clinical adverse reactions possibly, probably, or definitely related to the drug itself. The treatment of severe Mazzotti reactions has not been subjected to controlled clinical trials. Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. Antihistamines and/or aspirin have been used for most mild to moderate cases. After treatment with microfilaricidal drugs, patients with hyperreactive onchodermatitis (sowda) may be more likely than others to experience severe adverse reactions, especially edema and aggravation of onchodermatitis. Rarely, patients with onchocerciasis who are also heavily infected with Loa loa may develop a serious or even fatal encephalopathy either spontaneously or following treatment with an effective microfilaricide. In these patients, the following adverse experiences have also been reported: back pain, conjunctival hemorrhage, dyspnea, urinary and/or fecal incontinence, difficulty in standing/walking, mental status changes, confusion, lethargy, stupor, or coma.

Therapeutic Class

Anthelmintic

Storage Conditions

Store below 30°C in a dry area. Protect yourself from the sun. Keep out of children's reach.